ATM-AVI

DRUG4 trials

Conditions

Complicated Intra-Abdominal Infections, cIAIsComplicated Intra-abdominal InfectionGram-negative Bacterial InfectionsHosptial Acquired PneumoniaSerious Bacterial InfectionVentilator Associated Pneumonia

Phase 2

Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)

CompletedNCT02655419

PfizerComplicated Intra-Abdominal Infections, cIAIs

Start: 2016-05-19End: 2017-10-26Updated: 2020-04-02

Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections

RecruitingNCT05639647

PfizerGram-negative Bacterial Infections

Start: 2023-04-18End: 2026-08-17Target: 48Updated: 2026-03-25

Phase 3

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

CompletedNCT03329092

PfizerComplicated Intra-abdominal Infection, Hosptial Acquired Pneumonia, Ventilator Associated Pneumonia

Start: 2018-04-05End: 2023-02-23Updated: 2024-12-10

Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

TerminatedNCT03580044

PfizerSerious Bacterial Infection

Start: 2020-12-25End: 2023-01-23Updated: 2024-02-02

2025-11-21

Population pharmacokinetic/pharmacodynamic modeling to optimize aztreonam-avibactam dose regimens for adult patients

Antimicrobial Agents and Chemotherapy2025-06-188 citations

P-1256. Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Aztreonam-Avibactam Dosing Regimens

Open Forum Infectious Diseases2025-01-292 citations

Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.

2024-10-0751 citations

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation

European Journal of Clinical Pharmacology2024-01-2222 citations

2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study

Open Forum Infectious Diseases2023-11-2725 citations

Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain

BMJ Open2022-02-012 citations

Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study

Journal of Antimicrobial Chemotherapy2019-12-06113 citations

ATM-AVI

Sponsors

Conditions

Phase 2

Phase 3

Related Papers